BLUEHOLE-NEW-CONSUMPTION
29.3.2022 04:15:10 CEST | Business Wire | Press release
China’s leading vaping media, Bluehole New Consumption, today publishes an industry comment on SMOORE‘s establishment of the world’s first E&L testing laboratory in the vaping industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220328005929/en/
Here below is the full article:
SMOORE, a global leader in offering vaping technology solutions, today announced the establishment of the world’s first extractable and leachable (E&L) testing laboratory in the vaping industry.
Built in the last half of 2021, this laboratory conducts qualitative and quantitative analytical testing and health risk assessment of E&L substances of electronic atomization components, including metals, plastics and other polymers.
As China’s first electronic atomization company to develop a PMTA (Premarket Tobacco Product Applications)-compliant assessment system, including physical tests, chemical tests, non-clinical testing and health risk assessment, SMOORE also set up this E&L testing laboratory based on PMTA safety requirements.
Moreover, SMOORE's E&L testing laboratory is in collaboration with SMITHERS, a world-leading provider of testing, consulting, information, and compliance services. For years, the two companies have worked closely on PMTA compliance.
Currently, most companies in the vaping industry rely on third-party laboratories for E&L testing while SMOORE has set up an in-house laboratory with comprehensive and advanced testing equipment. It follows the analytical methodology of the world’s leading E&L testing laboratories for medical devices.
As SMOORE’s flagship atomization tech brand, FEELM is able to make full use of SMOORE’s world-class testing and risk assessment system, including this E&L testing laboratory. Since 2021, FEELM has leveraged the laboratory for the safety assessment of its electronic atomization components, to guarantee the quality and reliability of FEELM's new products.
In October 2021, the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK has planned to integrate medicinally licensed e-cigarettes into the National Health Service (NHS). Other countries, including Australia, have also prescribed adult smokers e-cigarettes to reduce smoking rates. As global regulators started embracing e-cigarettes, they are setting higher safety requirements for e-cigarettes, and SMOORE takes the lead to improve the material reliability of e-cigarettes to medical grade.
E&L analytical testing is widely used in the field of pharmaceutical research and development. The E&L compounds of the packaging materials of pharmaceutical products must be tested before launch, to ensure the product safety compliance.
SMOORE's E&L testing laboratory can provide safety assessment for not only e-cigarettes but also electronic atomization products in other sectors. With one of its R&D focus on the application of atomization technology in healthcare and pharmaceutical fields, SMOORE could leverage this laboratory for the development of healthcare atomization innovations.
"The safety of electronic atomization products primarily depends on the chemical composition of e-liquid and the vapor generated by e-liquid atomization, as well as the E&L substances of other materials in contact with human bodies", said Dr. Long, Director of Analytical Testing and Safety Assessment of SMOORE Fundamental Research Center. "Our E&L testing laboratory specializes in the latter."
According to Dr. Long, SMOORE Fundamental Research Center plans to establish and complete a database of E&L substances in electronic atomization components, and will adopt the principle of Good Laboratory Practice (GLP) to ensure the quality and integrity of test data related to non-clinical safety studies. Meanwhile, SMOORE Fundamental Research Center is also looking for partnership with more Chinese medical device providers on E&L testing.
Since 2020, SMOORE has established its own safety standards, SMOORE 3.0, in accordance with the risk assessment guidance of U.S. EPA (Environmental Protection Agency). Above the safety requirements of the Tobacco Products Directive (TPD) of the EU and AFNOR of France, SMOORE 3.0 covers all of the PMTA tests, including both material safety and vapor safety.
To read the original article, please visit: https://www.bluehole.com.cn/news/detail/49078
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005929/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
